Cellectis (NASDAQ:CLLS) Share Price Passes Below 50 Day Moving Average – Here’s Why

Cellectis S.A. (NASDAQ:CLLS)’s share price crossed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $4.44 and traded as low as $4.36. Cellectis shares last traded at $4.41, with a volume of 32,000 shares trading hands.

Analyst Ratings Changes

A number of equities research analysts have weighed in on CLLS shares. Clear Str upgraded Cellectis to a “strong-buy” rating in a research report on Tuesday, December 23rd. Barclays boosted their price objective on Cellectis from $4.00 to $8.00 and gave the stock an “overweight” rating in a research note on Friday, October 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cellectis in a research note on Wednesday, October 8th. Wells Fargo & Company reiterated a “positive” rating and issued a $4.00 price target on shares of Cellectis in a research report on Monday, October 20th. Finally, Wall Street Zen raised shares of Cellectis to a “hold” rating in a research note on Saturday, September 20th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $6.00.

Cellectis Stock Down 1.6%

The firm’s fifty day simple moving average is $4.44 and its 200 day simple moving average is $3.39. The company has a quick ratio of 1.49, a current ratio of 1.49 and a debt-to-equity ratio of 0.63.

Cellectis (NASDAQ:CLLS) last released its quarterly earnings results on Friday, November 7th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.11. Cellectis had a negative net margin of 58.06% and a negative return on equity of 51.22%. The business had revenue of $37.16 million for the quarter, compared to analyst estimates of $8.22 million. As a group, analysts anticipate that Cellectis S.A. will post -0.46 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Cellectis by 228.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,722,664 shares of the biotechnology company’s stock worth $5,856,000 after acquiring an additional 3,284,409 shares in the last quarter. Citadel Advisors LLC acquired a new position in shares of Cellectis in the 3rd quarter valued at about $633,000. Acadian Asset Management LLC increased its holdings in shares of Cellectis by 132.9% in the 1st quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 26,461 shares during the period. Virtu Financial LLC purchased a new stake in shares of Cellectis in the third quarter worth approximately $72,000. Finally, B Group Inc. boosted its holdings in shares of Cellectis by 0.8% during the third quarter. B Group Inc. now owns 3,281,501 shares of the biotechnology company’s stock worth $9,352,000 after purchasing an additional 25,000 shares during the period. Hedge funds and other institutional investors own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.